Standard adjuvant chemotherapy

DRUG2 trials

Sponsors

Hoffmann-La Roche, University Hospital, Rouen

Conditions

Breast CancerResectable Pancreatic Duct Adenocarcinoma

Phase 2

Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma

CompletedNCT02959879

University Hospital, RouenResectable Pancreatic Duct Adenocarcinoma

Start: 2017-03-01End: 2023-08-08Updated: 2026-02-06

Phase 3

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

CompletedNCT00528567

Hoffmann-La RocheBreast Cancer

Start: 2007-12-31End: 2014-06-30Updated: 2015-09-04

Related Papers

Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study)

Journal of Clinical Oncology2025-04-0417 citations

Abstract 2796: ctDNA prognosis in adjuvant triple-negative breast cancer

Cancer Research2022-06-152 citations

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: A multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).

Journal of Clinical Oncology2022-06-0133 citations

A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial

Therapeutic Advances in Medical Oncology2020-01-0113 citations

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).

2018-07-2479 citations

Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer.

2017-04-0179 citations

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.

2013-08-07297 citations